Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Xencor Inc (XNCR)

Xencor Inc (XNCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,755,718
  • Shares Outstanding, K 59,698
  • Annual Sales, $ 275,110 K
  • Annual Income, $ 82,630 K
  • 60-Month Beta 0.61
  • Price/Sales 6.37
  • Price/Cash Flow 18.21
  • Price/Book 2.36
Trade XNCR with:

Options Overview Details

View History
  • Implied Volatility 82.55% ( +19.05%)
  • Historical Volatility 40.04%
  • IV Percentile 81%
  • IV Rank 73.23%
  • IV High 99.21% on 05/18/22
  • IV Low 36.97% on 01/20/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 21
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 557
  • Open Int (30-Day) 489

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.72
  • Number of Estimates 4
  • High Estimate -0.48
  • Low Estimate -0.95
  • Prior Year -0.69
  • Growth Rate Est. (year over year) -4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.63 +13.97%
on 08/04/22
31.93 -8.52%
on 07/11/22
-2.83 (-8.83%)
since 07/08/22
3-Month
19.35 +50.92%
on 06/14/22
33.44 -12.65%
on 07/07/22
+4.56 (+18.50%)
since 05/09/22
52-Week
19.35 +50.92%
on 06/14/22
43.61 -33.02%
on 11/03/21
-1.44 (-4.70%)
since 08/09/21

Most Recent Stories

More News
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of -26.67% and 12.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

XNCR : 29.21 (-0.68%)
COLL : 19.35 (-0.77%)
Xencor Reports Second Quarter 2022 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results...

XNCR : 29.21 (-0.68%)
Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies

/PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to...

XNCR : 29.21 (-0.68%)
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release...

XNCR : 29.21 (-0.68%)
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation...

XNCR : 29.21 (-0.68%)
Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues

Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines....

AZN : 65.89 (+1.18%)
IRWD : 11.84 (+1.20%)
ABBV : 140.25 (-0.06%)
XNCR : 29.21 (-0.68%)
Zacks.com featured highlights Xencor, Encore Wire and Silvergate Capital

Xencor, Encore Wire and Silvergate Capital have been highlighted in this Screen of The Week article.

SI : 100.25 (-4.18%)
WIRE : 120.75 (-1.74%)
XNCR : 29.21 (-0.68%)
Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

XNCR : 29.21 (-0.68%)
ENTA : 68.27 (-4.21%)
Xencor Reports First Quarter 2022 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results...

XNCR : 29.21 (-0.68%)
Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

PCRX : 58.32 (-0.32%)
XNCR : 29.21 (-0.68%)
CRBP : 0.2500 (-6.37%)
SLNO : 0.1734 (-2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

3rd Resistance Point 31.23
2nd Resistance Point 30.54
1st Resistance Point 29.88
Last Price 29.21
1st Support Level 28.53
2nd Support Level 27.84
3rd Support Level 27.18

See More

52-Week High 43.61
Fibonacci 61.8% 34.34
Fibonacci 50% 31.48
Last Price 29.21
Fibonacci 38.2% 28.62
52-Week Low 19.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar